A patient with high-level paraplegia can control a robotic arm and shop online using only "thoughts"—this is the latest clinical trial result from StairMed's WRS01. A reporter recently visited industry chain companies such as StairMed, Xinzhida, and Xiangyu Medical and found that China's brain-computer interface sector is advancing through multi-point coordination: semi-invasive and invasive product registration and clinical trials are proceeding in an orderly manner, independent research on core components such as electrodes continues to deepen, and non-invasive brain-computer rehabilitation equipment is accelerating its deployment in medical institutions. The industry is moving beyond conceptual verification and one-sided, extensive competition over channel parameters, and entering a new cycle with long-term safety and clinical efficacy as the core benchmarks. Sector enthusiasm continues to rise, but most products are still in the clinical validation cycle, and industrialization remains subject to multiple tests. With the implementation of the international standard for brain-computer interface reference architecture led by China, coordination among capital, clinical practice, and the industry chain is accelerating, driving brain-computer technology from the laboratory to real medical scenarios.